Results from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.

Sexual function data support enzalutamide use in men with high-risk biochemically recurrent (BCR) prostate cancer.

Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic ...

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

New research from Edith Cowan University (ECU) has confirmed that erectile dysfunction in patients living with prostate ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

A new study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ...

Colon cancer occurs when cells in your large intestine grow out of control. Treatment can vary by the stage and type of colon cancer. Colon cancer is a type of cancer that starts in your colon ...

Rishi Sunak met workers developing a new blood test for the disease last week Former prime minister Rishi Sunak has said he is "honoured" to become a prostate cancer charity ambassador.

Former prime minister Rishi Sunak has said he is "honoured" to become a prostate cancer charity ambassador. He will support Prostate Cancer Research's campaign to introduce a national screening ...

In evidence provided to the BBC, the National Cancer Audit Collaborating Centre (NatCan) highlighted particular problems with prostate, kidney and colon cancers. The expert group said it had found ...

The latest figures on prostate cancer are shocking: it has officially overtaken breast cancer as the most commonly diagnosed cancer in England, according to NHS figures. These show a massive 25 ...